Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    23841729 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Realgar-Indigo naturalis formula;   Drug: all-trans retinoic acid;   Drug: Arsenic trioxide;   Drug: Hydroxyurea
2 Active, not recruiting Phase III Trial in Acute Promyelocytic Leukemia Patients
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: all-trans retinoic acid;   Drug: all-trans retinoic acid (ATRA)

Indicates status has not been verified in more than two years